Tau catalyzes amyloid-β aggregation and toxicity in a polymorph-dependent manner

M Michele Mosconi (Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare) C Chiara Leonardi (Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare) Z Zev Armour-Garb (Center for Misfolding Diseases, Yusuf Hamied Department of Chemistry, Cambridge University) B Beatrice Rocutto (Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare) M Marten Beeg (Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare) G Georg Meisl (Yusuf Hamied Department of Chemistry) L Lei Ortigosa-Pascual (Biochemistry and Structural Biology, Department of Chemistry, Lund University) L Luca Broggini (Department of Biosciences, Università degli Studi di Milano) M Mario Salmona (Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare) S Stefano Ricagno (Department of Biosciences, Università degli Studi di Milano) T Tuomas P. J. Knowles L Luisa Diomede (Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare)

Abstract

Interactions between amyloidogenic proteins are emerging as critical drivers of neurodegenerative diseases. Among others, in Alzheimer’s disease (AD) and severe forms of chronic traumatic encephalopathy (CTE), codeposition of tau and amyloid-β (Aβ) leads to worsening of clinical outcomes and disease progression. Despite the importance of such heterotypic interactions, the underlying molecular mechanisms have proven challenging to be established. Here, we investigated the direct interaction between Aβ and tau, combining in vitro reconstruction, and in vivo models. We find that characteristic AD paired helical filament (PHF) and CTE folds catalyze the primary nucleation of Aβ42 in a fold-specific manner with enzyme-like kinetics. In particular, CTE fibrils exhibit the highest catalytic activity and constrain Aβ42 polymorphism, suggesting templating effects. Moreover, PHF and CTE tau fibrils increase Aβ42 toxicity in SH-SY5Y neuroblastoma cells and transgenic Caenorhabditis elegans, preserving fold-dependent reactivities. Our findings shed light on the molecular mechanisms of heterotypic interaction between amyloidogenic proteins in disease-relevant conditions, highlighting the role of amyloid structure and recognition mechanisms as key determinants. These results offer insights into the pathological mechanisms of multiple proteinopathies. The mechanisms described here might be used as a blueprint for structure-based design of new therapeutic agents targeting specific amyloidogenic interactions.

Article Details

Volume / Issue Vol. 123, Issue 13
Published March 31, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (12)

M

Michele Mosconi

Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare

C

Chiara Leonardi

Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare

Z

Zev Armour-Garb

Center for Misfolding Diseases, Yusuf Hamied Department of Chemistry, Cambridge University

B

Beatrice Rocutto

Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare

M

Marten Beeg

Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare

G

Georg Meisl

Yusuf Hamied Department of Chemistry

L

Lei Ortigosa-Pascual

Biochemistry and Structural Biology, Department of Chemistry, Lund University

L

Luca Broggini

Department of Biosciences, Università degli Studi di Milano

M

Mario Salmona

Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare

S

Stefano Ricagno

Department of Biosciences, Università degli Studi di Milano

T

Tuomas P. J. Knowles

L

Luisa Diomede

Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri Scientific Institutes for Research, Hospitalization and Healthcare